All news

Viking Therapeutics (VKTX) As SUNRISE Phase 3 Starts Is The Stock Fully Priced

Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash

Viking Therapeutics (VKTX) has initiated its SUNRISE Phase 3 program for oral VK2735, following successful Phase 2 trials and fully enrolled injectable trials. Despite this progress, the stock has seen a significant pullback, with its share price down over 30% in 90 days and 28.9% year-to-date, suggesting that traders are reassessing trial risks and timing.

Read original source

VKTX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.